Want to use our logo?

Download the ICS Branding Pack

ICS Background

Prof Martin Christian Michel
Johannes Gutenberg University

ICS 2019

Open Discussion ePoster Session 18 E-Poster 2 383 A survey on the preferred use of CME activities by healthcare professionals in urological care

Open Discussion ePoster Session 31 E-Poster 3 573 Correlation of pad use with specific overactive bladder symptoms: findings at baseline and after treatment in two non-interventional studies

Open Discussion ePoster Session 31 E-Poster 3 574 Do patient perception and objective symptoms correlate in patients with overactive bladder syndrome? An analysis based on Patient Perception of Bladder Condition

Open Discussion ePoster Session 31 E-Poster 3 594 Revisiting the relationship between overactive bladder syndrome and the frequency-urgency syndrome

ICS 2018

Podium Short Oral Session 33 Overactive Bladder 2 651 Do overactive bladder symptoms exhibit a Gaussian distribution? Implications for reporting of clinical trial data

Podium Short Oral Session 33 Overactive Bladder 2 654 Evidence-based management of overactive bladder patients: Expectation to become symptom-free

Non Discussion Abstract Session 36 Non Discussion Abstracts 725 A comparison of normalization approaches for in vitro contraction experiments of urinary bladder

ICS/IUGA 2010

Non Discussion Abstract Session 33 Read by Title 1051 Effects of concomitant diabetes on treatment responses to a muscarinic antagonist in overactive bladder patients

ICS 2009

Non Discussion Poster Session 32 338 Are overactive bladder symptoms related to the presence of arterial hypertension?

ICS 2008

Non Discussion Poster Session 19 218 Which measures of overactive bladder symptom treatment correlate best with patient satisfaction?

Non Discussion Poster Session 19 320 DOES THE NUMBER OF PREVIOUS VAGINAL DELIVERIES AFFECT OVERACTIVE BLADDER SYMPTOMS OR THEIR RESPONSE TO TREATMENT?

Non Discussion Poster Session 19 406 The centrally acting ion channel modulator flupirtine improves bladder function in animal models and patients with overactive bladder syndrome

View Member Details

Martin Michel

Member

Profession:Pharmacologist
Qualifications:PhD Professor
Privacy:
You must be logged in to view this contact
Sign-in to ICS

Dr. Martin C. Michel was born and raised in Germany. After studying medicine in Essen (Germany) and Vienna (Austria) he received his medical degree in 1985. Based upon a thesis in the Dept. of Biochemistry of the University of Essen he received a doctorate in 1987. He has worked as a post-doc in Essen (1985-1987) and at the University of California San Diego (1987-1990) and was appointed as Adjunct Assistant Professor in San Diego and as lecturer in Essen in 1991. He is a board-certified pharmacologist (1990) and clinical pharmacologist (1997). Between 1993 and 2002 he was head of the Nephrology and Hypertension Research Laboratory at the University of Essen. From 2003-2011 he was professor and head of the Department of Pharmacology & Pharmacotherapy at the University of Amsterdam (The Netherlands) and from 2011-2016 Global Head Product and Pipeline Scientific Support at Boehringer Ingelheim. Currently, he is a Professor of Pharmacology at the Johannes Gutenberg University in Mainz, Germany. He is a member of many national and international pharmacological and urological societies. He also is past Editor-in-Chief of Naunyn-Schmiedeberg’s Archives of Pharmacology and serves on the board of many pharmacological, physiological and urological journals including Molecular Pharmacology, American Journal of Physiology (Cell Physiology) and European Urology. Dr. Michel has published more than 300 articles in peer-reviewed journals. His most important award/distinct was the election into the Academia Europaea, the European academy of sciences.

SYNOPSIS OF AREA OF INTEREST: Dr. Michel’s research interests include urogenital and cardiovascular pharmacology and physiology spanning the entire range from molecular pharmacology to clinical trials.

Prof Martin Christian Michel declared on the Monday 25th January 2010 that they had the following existing or known future financial relationships or affiliations:

Elbion

  • Consultant
  • Trial participation

Allergan

  • Speaker Honorarium

Recordati

  • Consultant
  • Speaker Honorarium

Eli Lilly

  • Consultant

Bayer

  • Consultant
  • Trial participation

Pfizer

  • Consultant
  • Speaker Honorarium
  • Trial participation

Boehringer

  • Consultant
  • Speaker Honorarium
  • Trial participation

Astellas

  • Consultant
  • Speaker Honorarium
  • Trial participation
  • Research grant
VOLUNTARY (EXPIRED)